Daxas
-
Nycomed and Merck & Co Announce Commercialization Agreements in Europe and Canada
Nycomed and Merck & Co have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas (roflumilast), an investigational once-daily tablet for patients with Chronic Obstructive Pulmonary Disease…
Daxas | 29 April 2010
